Overexpression of CDCA2 in Diffuse Large B-Cell Lymphoma Promotes Cell Proliferation and Bortezomib Sensitivity
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125596 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hanne Due und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Bortezomib, Cell Cycle Proteins, Nuclear Proteins. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Cancer Society, A.P Moeller Foundation, The Danish Cancer Society.
Abstract (Originalsprache)
Numerous clinical trials have attempted to improve first-line R-CHOP treatment of diffuse large B-cell lymphoma (DLBCL) through the addition or substitution of drugs. The REMoDL-B trial, testing the addition of bortezomib (RB-CHOP), revealed that ABC and molecular high-grade DLBCL patients benefit from bortezomib. The aim of this study was to achieve a better understanding of the bortezomib response in DLBCL through a functional investigation of clinically identified markers. A retrospective analysis of transcriptional and clinical data from the REMoDL-B trial was conducted to identify genes associated with bortezomib response, identifying CDCA2. DLBCL patients with high expression of CDCA2 had a superior survival outcome when treated with RB-CHOP in comparison to R-CHOP, whereas no difference in outcome was observed for patients with low CDCA2. Moreover, CDCA2 was found to be overexpressed in DLBCL compared to non-malignant tissue, and to have higher levels in GCB and MYC/BCL2 double-expressor patients. Functional in vitro and in vivo studies revealed that knockout of CDCA2 decreased DLBCL cell proliferation and a bortezomib dose–response analysis showed less sensitivity in CDCA2 knockout cells compared to control cells. This study shows that DLBCL patients with high CDCA2 expression benefitted from the addition of bortezomib to R-CHOP and functional studies documented a direct impact of CDCA2 on the bortezomib response in DLBCL cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, 9000 Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, 9260 Gistrup, Denmark.
- Center for Clinical Data Science, Aalborg University Hospital, and Aalborg University, 9260 Gistrup, Denmark.
- Department of Health Science and Technology, Aalborg University, 9260 Gistrup, Denmark.
- Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark.
ORCID-Profile: Hanne Due, Asta Brogaard, Issa Ismail Issa, Maja Zimmer Jakobsen, Cathrine Sylvester, Martin Kristian Thomsen, Rasmus Froberg Brøndum, Karen Dybkær
Förderung
- Danish Cancer Society
- A.P Moeller Foundation
- The Danish Cancer Society
- A.P. Moeller Foundation
Zitieren
APA
Due, H., Brogaard, A., Issa, I. I., Jakobsen, M. Z., Sylvester, C., Nøhr, A. K., Thomsen, L. B., Thomsen, M. K., Brøndum, R. F., & Dybkær, K. (2025). Overexpression of CDCA2 in Diffuse Large B-Cell Lymphoma Promotes Cell Proliferation and Bortezomib Sensitivity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125596
Vancouver
Due H, Brogaard A, Issa II, Jakobsen MZ, Sylvester C, Nøhr AK, et al. Overexpression of CDCA2 in Diffuse Large B-Cell Lymphoma Promotes Cell Proliferation and Bortezomib Sensitivity. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125596
BibTeX
@article{Due2025,
author = {Due, Hanne and Brogaard, Asta and Issa, Issa Ismail and Jakobsen, Maja Zimmer and Sylvester, Cathrine and Nøhr, Anne Krogh and Thomsen, Louiza Bohn and Thomsen, Martin Kristian and Brøndum, Rasmus Froberg and Dybkær, Karen},
title = {Overexpression of CDCA2 in Diffuse Large B-Cell Lymphoma Promotes Cell Proliferation and Bortezomib Sensitivity},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125596}
}
EUVIMED